Incidental prostate adenocarcinoma (IPCa) has been frequently discovered during postoperative histopathological evaluation of radical cystoprostatectomy specimens in patients with bladder cancer (BCa). However, there is currently no conclusive study addressing the clinical significance of IPCa and the clonal relatedness of IPCa and BCa. Here, we performed a retrospective single-center review of 919 BCa cases and an additional meta-analysis including a total of 19 868 individuals who underwent radical cystectomy for bladder cancer. IPCa, mostly clinically insignificant, was detected in 67 of 919 BCa patients (7.3%) and was significantly associated with greater age. In the meta-analysis, a lower prevalence was observed in Asian than in non-Asian countries (19% versus 32%), presumably due to their different rates of prostate cancer occurrence. Whole-exome sequencing on matched BCa and IPCa samples unambiguously revealed independent clonal origins of the synchronous tumors. BCa and IPCa lesions from each patient displayed distinctive genomic abnormalities and largely unrelated mutational signatures of single nucleotide variations, indicating disparate mutational processes underlying bladder and prostate oncogenesis. These findings provide important insights into the incidental nature of prostate adenocarcinoma in patients with bladder cancer, and suggest that the two concurrent diseases can be managed separately.
Introduction
Incidental prostate adenocarcinoma (IPCa), present in patients with bladder cancer (BCa), has been frequently observed during postoperative pathological examination of cystoprostatectomy specimens. Despite extensive previous investigations and emerging consensus on the paramount importance of precise diagnosis, the prevalence, pathological characteristics, clinical significance, and standardized management of synchronous primary carcinomas in the bladder and prostate remain unclear and often controversial in the literature [1] [2] [3] . In addition, the relationships between concomitant IPCa and BCa and their molecular origins have not been comprehensively characterized [1, 4] . Therefore, we reasoned that a systematic meta-analysis in combination with a detailed genomic description might enhance our understanding of the clinical relevance and genetic relatedness of simultaneous BCa and IPCa in a given patient.
Materials and methods

Patient cohort
Written informed consent was obtained from all subjects. Samples for sequencing were collected from patients with bladder cancer who underwent radical cystoprostatectomy in Ren Ji Hospital, Shanghai Jiao Tong University. Details of the clinical characteristics are provided in the supplementary material, Table S1 . All samples were subjected to whole-exome sequencing (WES). Between 1999 and 2017, 919 patients who had been diagnosed with bladder cancer and treated at Ren Ji Hospital were included in the retrospective analysis. Clinical information including age at diagnosis, 
Meta-analysis
A systematic search was conducted in the PubMed database for original publications between 1988 and 2017. Details of the selected studies are provided in the supplementary material, Table S2 . Review Manager Software version 5.3 (The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen, Denmark) was used for the meta-analysis.
Whole-exome sequencing and driver mutation identification
Genomic DNA of tumor and paired normal tissue was extracted from ten formalin-fixed and paraffin-embedded (FFPE) sections with a thickness of 10 μm, using a QIAamp DNA FFPE Tissue Kit (Qiagen, Germantown, MD, USA). Library construction, sequence alignment [6] , and variant calling [7, 8] are described in the supplementary material, Supplementary materials and methods. The targeted sequencing depth was 200×. The sequencing data have been deposited in the NCBI Sequence Read Archive (https://www.ncbi.nlm.nih.gov/sra) under the accession number SRP110960. Additional filtering was applied to exclude artefactual mutations produced by formalin fixation and paraffin embedding of the specimens (see supplementary material, Supplementary materials and methods). All identified non-synonymous mutations were compared with potential driver genes in bladder cancer or present in the COSMIC cancer gene census. Criteria for determining putative driver mutations are described in the supplementary material, Supplementary materials and methods.
Mutational signature generation
All somatic SNVs were included to calculate the relative weights of mutational signatures in a given sample. The R package 'deconstructSigs', based on the Wellcome Trust Sanger Institute Mutational Signature Framework (http://cancer.sanger.ac.uk/cosmic/signatures), was used to statistically quantify the contribution of each signature for each tumor.
Bioinformatic analysis and statistical analysis
Clonal relatedness was determined by clonality indices calculation as previously described [9] . The SciClone R package (https://github.com/genome/sciclone) and PyClone (http://compbio.bccrc.ca/software/pyclone/) were employed to detect the subclonality of a given sample [10, 11] 
Results and discussion
We analyzed the prevalence and characteristics of IPCa by performing a retrospective review of 919 consecutive BCa patients who underwent radical cystoprostatectomy in our hospital between 1999 and 2017. A total of 67 males (7.3%) with BCa had pathologically confirmed synchronous IPCa following postoperative whole-mount prostate examination. The diagnosis of IPCa ( Figure 1A ), mostly clinically insignificant (71.6%, 48 out of 67), was associated with greater patient age (P = 0.011, chi-squared test) but not bladder tumor stage, grade or lymph node metastasis (Table 1) . To validate these findings, we further conducted a systematic meta-analysis of 58 studies including 19 868 patients (supplementary material, Table S2 ). Consistently, IPCa was more likely to be detected in older patients (supplementary material, Figure S1A ), and 71.5% of IPCa neoplasms were clinically insignificant (supplementary material, Figure S1B ). A statistically significant geographical difference in IPCa incidence was observed ( Table 2 ), in that Asian populations displayed a lower prevalence (19.4 ± 3.3%) than non-Asian countries (31.8 ± 2.3%), in accordance with their different rates of prostate cancer occurrence [12] . The proportions of clinically significant IPCa were comparable between the two populations (45.0% versus 41.8%). Although BCa in non-Asian patients tended to be more advanced (Table 2) , the comparison between the prevalence of IPCa and BCa stage (supplementary material, Figure S2A ) or lymph node dissemination (supplementary material, Figure S2B ) demonstrated no significant association. Biochemical recurrence of prostate cancer occurred in only four cases in our single-center cohort, with no IPCa-caused deaths during the follow-up, and patient prognosis was simply related to BCa. Taken together, the clinicopathological characteristics of IPCa largely resembled the epidemiological data of prostate cancer in the general population regarding patient age and ethnic groups, and little evidence supported the interplay between BCa and IPCa.
As a complementary approach, we sampled 13 cases of synchronous BCa and IPCa (RJBC1-13; supplementary material, Table S1 ) and performed whole-exome sequencing on matched bladder and prostate tumors, with pathologically normal bladder tissues as controls. Since archived formalin-fixed and paraffin-embedded (FFPE) specimens were used, sequencing data from only four patients passed stringent quality control (RJBC1-4), yielding a mean coverage of 218× (101-365×) . Approximately 95.2% of targeted Figure S4 ) and PyClone (supplementary material, Figure S5 ). There was a pronounced discrepancy in the numbers of genomic alterations ( Figure 1C and supplementary material, Figure S6A ), significantly mutated genes (supplementary material, Figure S6B ), putative driver aberrations (supplementary material, Figure S6C and Table S5) , and patterns of mutation spectra ( Figure 1D ) between BCa and IPCa from each of the individuals, implying that the two tumors within each subject probably arose autonomously from different progenitor cells. In agreement with this notion, appreciably overlapping repertoires of somatic variants were absent between each tumor pair in these four patients (Figure 2A) , and a conservative analytic approach to estimate the clonality Synchronous tumors in the bladder and prostate arise independently 9 indices indicated that matched bladder and prostate cancers were clonally unrelated with no exception ( Figure 2B ). Based on these results, we concluded that IPCa associated with BCa formed through independent multifocal tumorigenesis. It has been reported that the coincidence rate between bladder and prostate cancer is significantly higher than the expected diagnosis frequency on the basis of disease prevalence in the general population [13, 14] . Although the likelihood of diagnostic bias may exist, the detection of one genitourinary tumor leading to a more extensive pathologic assessment [15] and regular clinical follow-up of other neoplastic lesions. In addition, preliminary evidence supports common carcinogenic pathways underlying the pathogenesis of both cancers, which could explain the increased risk of developing these two malignancies in certain patients [16] . Following this hypothesis, we assessed the potentially shared etiologies of BCa and IPCa by performing a detailed analysis on 96 possible mutation types of both tumors. In all four patients, different patterns of mutation combinations within BCa and IPCa were observed, suggesting that distinct mutational machineries were operating to shape bladder or prostate tumorigenesis in each case ( Figure 2C ). We further used the deconstructSigs framework to extract known mutational signatures that might contribute to the specific mutational profiles in every tumor ( Figure 2D and supplementary material, Figure S7 ). Notably, somatic mutations of bladder cancer generally exhibited an enrichment of heterogeneous mutational signatures, including signature 1 (age-related), signature 2/13 (attributed to the activity of AID/APOBEC cytidine deaminases), signature 6/15 (associated with defective DNA mismatch repair), and signature 10 (attributable to altered activity of the error-prone polymerase POLE). In contrast, prostate cancer mutagenesis was almost exclusively characterized by signature 1 (age-related). Other relevant mutational signatures included signature 6/15 (associated with defective DNA mismatch repair) and, interestingly, signature 24 (consistent with aflatoxin exposure). Of note, our findings were consistent with previous studies that revealed a major role for APOBEC-mediated mutagenesis in bladder, but not prostate, carcinogenesis [17, 18] . The shared DNA repair-related signatures within BCa and IPCa prompted us to analyze both germline and somatic mutations in the DNA repair pathway, and indeed, multiple genetic alterations were identified (supplementary material, Figure S8 ), although their functional relevance remained to be elucidated. Together, these results pinpointed differential contributions of diverse mutational processes in BCa and IPCa, and argued that the speculated mechanistic relationship between the two cancer types warranted further investigation.
Previous retrospective studies have mainly centered on the clinicopathological features of IPCa in BCa cystoprostatectomy specimens, and different reports reached varied conclusions [2] [3] [4] 19] . In this study, we have presented the largest Asian cohort of 919 BCa cases and a systematic meta-analysis of 19 868 patients who received radical cystectomy for bladder cancer. In addition, comprehensive genomic interrogation of synchronous BCa and IPCa was applied to resolve the clonal relationship of co-existent primary tumors. Both lines of evidence unambiguously oppose a conjectural pathogenetic interaction between the two cancer entities. We propose that until concrete evidence for a causative association emerges, concurrent BCa and IPCa should be considered as independent malignancies and managed separately in clinic. Table S1 . Patient cohort for whole-exome sequencing Table S2 . Studies included in meta-analysis Table S3 . Sequencing statistics Table S4 . All mutations in each sample Table S5 . Driver mutation analysis
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